JP2019511533A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511533A5
JP2019511533A5 JP2018553428A JP2018553428A JP2019511533A5 JP 2019511533 A5 JP2019511533 A5 JP 2019511533A5 JP 2018553428 A JP2018553428 A JP 2018553428A JP 2018553428 A JP2018553428 A JP 2018553428A JP 2019511533 A5 JP2019511533 A5 JP 2019511533A5
Authority
JP
Japan
Prior art keywords
dengue
chimera
den
pharmaceutical composition
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018553428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511533A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/052160 external-priority patent/WO2017179017A1/en
Publication of JP2019511533A publication Critical patent/JP2019511533A/ja
Publication of JP2019511533A5 publication Critical patent/JP2019511533A5/ja
Priority to JP2022069423A priority Critical patent/JP2022089964A/ja
Priority to JP2024044760A priority patent/JP2024071463A/ja
Pending legal-status Critical Current

Links

JP2018553428A 2016-04-13 2017-04-13 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 Pending JP2019511533A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022069423A JP2022089964A (ja) 2016-04-13 2022-04-20 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2024044760A JP2024071463A (ja) 2016-04-13 2024-03-21 小児及び若年成人のデングウイルスに対するワクチンの組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322167P 2016-04-13 2016-04-13
US62/322,167 2016-04-13
PCT/IB2017/052160 WO2017179017A1 (en) 2016-04-13 2017-04-13 Compositions and methods of vaccination against dengue virus in children and young adults

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022069423A Division JP2022089964A (ja) 2016-04-13 2022-04-20 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法

Publications (2)

Publication Number Publication Date
JP2019511533A JP2019511533A (ja) 2019-04-25
JP2019511533A5 true JP2019511533A5 (https=) 2020-05-14

Family

ID=58671740

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018553428A Pending JP2019511533A (ja) 2016-04-13 2017-04-13 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2022069423A Pending JP2022089964A (ja) 2016-04-13 2022-04-20 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2024044760A Withdrawn JP2024071463A (ja) 2016-04-13 2024-03-21 小児及び若年成人のデングウイルスに対するワクチンの組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022069423A Pending JP2022089964A (ja) 2016-04-13 2022-04-20 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2024044760A Withdrawn JP2024071463A (ja) 2016-04-13 2024-03-21 小児及び若年成人のデングウイルスに対するワクチンの組成物

Country Status (14)

Country Link
US (3) US11007261B2 (https=)
EP (1) EP3442571A1 (https=)
JP (3) JP2019511533A (https=)
KR (1) KR102611235B1 (https=)
CN (2) CN109069615B (https=)
AU (2) AU2017250696A1 (https=)
BR (1) BR112018071087A2 (https=)
CA (1) CA3020484A1 (https=)
CO (1) CO2018011355A2 (https=)
MX (1) MX2018012459A (https=)
MY (1) MY192806A (https=)
PH (1) PH12018502175B1 (https=)
SG (2) SG11201808906RA (https=)
WO (1) WO2017179017A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
US11007261B2 (en) * 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
TWI766876B (zh) * 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
WO2019112921A1 (en) * 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
WO2020051334A1 (en) * 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
MX2022001742A (es) * 2019-08-16 2022-04-07 Takeda Vaccines Inc Metodos para prevenir el dengue y la hepatitis a.
EP4110381A1 (en) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
EP3892737A1 (en) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4357464A1 (en) * 2022-10-20 2024-04-24 Takeda Vaccines, Inc. A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
WO2024097725A1 (en) * 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus
EP4375381B1 (en) 2022-11-18 2026-02-25 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation
CN120529951A (zh) 2022-11-29 2025-08-22 武田疫苗股份有限公司 大规模黄病毒疫苗生产和制造
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481982T1 (de) * 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
NZ597000A (en) 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2771366A4 (en) * 2011-10-25 2015-06-03 Florida Gulf Coast University Board Of Trustees VACCINES AND METHOD FOR PRODUCING A VACCINE FOR INDUCING IMMUNITY AGAINST ALL SERGENT TYPES OF THE DENGUE VIRUS
NZ630831A (en) * 2012-06-10 2019-02-22 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
MX381497B (es) * 2012-07-24 2025-03-12 Sanofi Pasteur Composiciones vacuna.
TW201920677A (zh) * 2012-11-08 2019-06-01 美商武田疫苗股份有限公司 登革熱病毒血清型４型之建構物的組成物、方法及用途
JP2016504315A (ja) 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
HRP20231581T1 (hr) * 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
US11007261B2 (en) * 2016-04-13 2021-05-18 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
WO2020051334A1 (en) * 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Similar Documents

Publication Publication Date Title
JP2019511533A5 (https=)
CN101454022B (zh) 假性感染性黄病毒及其用途
Khetarpal et al. Dengue fever: causes, complications, and vaccine strategies
Pletnev et al. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus
Pugachev et al. New developments in flavivirus vaccines with special attention to yellow fever
Lanciotti et al. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East
JP4993301B2 (ja) 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
ES2677348T3 (es) Un virus del dengue quimérico recombinante rDEN3/4delta 30(ME), rDEN2/4delta30(ME) o rDEN1/4delta30(ME) que contiene una deleción de 30 nucleótidos (delta30) en una sección de la región no traducida en 3' del genoma del dengue de tipo 4, en donde dicha deleción de 30 nucleótidos se corresponde con la estructura tallo-bucle de TL2
Monath et al. West Nile virus vaccine.
US9499588B2 (en) Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof
Huang et al. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus
AU2017250696A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
JP2016513970A5 (https=)
JP5469336B2 (ja) 組換えフラビウイルスワクチン
JP2019511221A (ja) 弱毒化された生ジカウイルスワクチン
WO2018129160A1 (en) Live attenuated flavivirus vaccines and methods of using and making same
ES2444691T3 (es) Proteína de la cápside del virus del Dengue que induce una respuesta protectora y su composición farmacéutica
ES2637629T3 (es) Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
Pugachev et al. Chimeric vaccines against Japanese encephalitis, dengue, and West Nile
Simasathein et al. Dengue vaccine
Pulmanausahakul et al. The development of flavivirus vaccines
AU2019203166A1 (en) Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
HK1120431A (en) Recombinant flavivirus vaccines